HOMO- AND HETERO-POLYAMINO-ACID DERIVATIVES OF FULLERENE C60, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITIONS BASED ON SAID DERIVATIVES

The invention relates to the pharmaceutical industry and to medicine, specifically to novel homo- and hetero-polyamino-acid derivatives of fullerene Cof general formula: C(H){NH(CH)COO—}{NH(L)COOH)}, where n=2-5, x=3, L=—(CH), where m=1-5, or —CO(CH)CH(NH)—, where k=1-2, characterized in that the compounds comprise covalently bonded amino-acid groups and polar ionic forms of the amino acids, and also to a method for producing said derivatives, and to the production of pharmaceutical compositions based on same. The method for producing homo- and hetero-polyamino-acid derivatives of fullerene is based on the reaction of a nucleophilic bond of amino acids to fullerene, forming covalently bonded amino-acid derivatives of fullerene, with the subsequent introduction of polar ionic forms of the amino acids. A pharmaceutical composition comprises, as active substance, homo- and hetero-polyamino-acid derivatives of fullerene of formula 1. Homo- and heteropoly(amino acid) derivatives of fullerene of general formula C(H){NH(CH)COO—}{NH(L)COOH)} , wherein n=2-5 , x=3 , L=—(CH) , wherein m=1-5 , or —CO(CH)CH(NH)— , wherein k=1-2 , characterized in that the compounds comprise covalently bonded amino acid groups and polar ionic forms of amino acids.2. Fullerene derivatives according to claim 1 , characterized in that the amino acid groups are moieties of aliphatic amino acids of general formula NH(CH)COOH claim 1 , wherein n=2-5.3. Fullerene derivatives according to claim 1 , characterized in that the polar ionic forms of amino acids are moieties of dicaboxylic amino acid amides of general formula NH(CO)(CH)CH(NH)COOH claim 1 , wherein k=1-2.4. A method for producing the fullerene derivatives according to claim 1 , characterized in that the fullerene derivatives are produced by reacting fullerene with a tenfold molar excess of anhydrous potassium salts of amino acids of general formula NH(CH)COOK claim 1 , wherein n=2-5 claim 1 , in an aromatic organic solvent medium claim 1 , ...

HYDRATED N-FULLERENE AMINO ACIDS, METHOD FOR PRODUCING THE LATTER, AND PHARMACEUTICAL COMPOSITIONS ON THE BASIS THEREOF

The invention relates to the pharmaceutical industry and to medicine, specifically to novel hydrated amino-acid derivatives of fullerene Cof general formula C(H){NH(CH)COOH}.xHO, where C-fullerene, n=5, 6, 7, x=8-10, and also to a method for producing said derivatives, and to the production of pharmaceutical compositions on the basis thereof. Hydrated N-fullerene amino acids are formed in the interaction of fullerene with 15 times the molar excess of anhydrous potassium salts of amino acids in a medium of organic aromatic solvent with slow addition to the resultant suspension of an interphase catalyst and with mixing and heating to a temperature not exceeding 60° C. until the solution is completely decolorized and a solid residue formed, after which the latter is separated out, and then 0.8 M of aqueous solutions of potassium salts of fullerene amino-acid derivatives is treated with a solution of organic or mineral acids, followed by centrifugation, rinsing and drying of the residue. A pharmaceutical composition which exhibits activity against the herpes virus, flu viruses of various origin and HIV, and also anti-tumor and anti-psoriatic activity, comprising, as active substance, an effective quantity of hydrated N-fullerene amino acids. 1. Hydrated N-fullerene amino acids of general formula C(H){NH(CH)COOH}xHO , wherein Cis fullerene; n=5 , 6 , or 7; and x=8 to 10.2. A method for producing the compound according to claim 1 , characterized in that the fullerene is reacted with a 15-fold molar excess of anhydrous potassium salts of amino acids of general formula NH(CH)COOH claim 1 , wherein n=5 claim 1 , 6 claim 1 , or 7 claim 1 , in an aromatic solvent medium claim 1 , comprising a slow addition to the resulting suspension of a phase-transfer catalyst under stirring and heating to a temperature not higher than 60 to 80° C. until the solution is completely decolorized and a solid residue is formed claim 1 , wherein said residue represents potassium salts of the ...

WATER-SOLUBLE ANTIFOAM ADDITIVE FOR A CEMENT COMPOSITION, AQUEOUS SOLUTION CONTAINING SAME AND USE THEREOF IN MORTARS OR CONCRETES

An anti-foam additive for a cement composition, including a fatty alcohol ester that is soluble in an aqueous medium at acidic pH, and hydrolysable in a basic medium, i.e. when the ester is incorporated into the cement composition, while releasing an active anti-foam molecule. This ester is preferably a fatty alcohol ester of a quaternary ammonium carboxylate, that is soluble in an aqueous solution of a superplasticizer, such as a polycarboxylate with poly(ethylene oxide) side chains. The additive can used for reducing the amount of air entrained during mixing or blending of mortars or concretes. 1. An additive for a cementitious composition , based on cement and water , in particular for a cementitious composition prepared with addition of superplasticizer , characterized in that it is in the form of a fatty alcohol ester that is soluble in an aqueous medium at acid pH and hydrolysable during its incorporation into said cementitious composition , capable of releasing said fatty alcohol , the fatty alcohol being an active anti-foam molecule.3. The additive as claimed in claim 2 , characterized in that the fatty alcohol ester is a fatty alcohol ester of an N claim 2 ,N claim 2 ,N-trialkyl glycine claim 2 , with identical or different Cto Calkyl radicals claim 2 , preferably a fatty alcohol ester of N claim 2 ,N claim 2 ,N-trimethyl glycine.4. The additive as claimed in claim 1 , characterized in that the fatty alcohol (capable of being released during the hydrolysis of the ester in a basic medium) is a primary or secondary Cto C claim 1 , preferably Cto C claim 1 , alcohol that is saturated or that comprises at least one double bond.5. The additive as claimed in claim 1 , characterized in that the fatty alcohol is chosen from decanol claim 1 , undecanol claim 1 , lauryl alcohol claim 1 , tetradecanol claim 1 , oleyl alcohol claim 1 , 10-undecen-1-ol and 2-decanol.6. An aqueous solution of superplasticizer for a cementitious composition claim 1 , characterized in that ...

FATTY AMINO ALCOHOLS AND PROCESS FOR PREPARING SAME

The present invention relates to amino alcohol compounds and to the preparation thereof from fatty esters comprising at least two carbon-carbon double bonds. In particular, the present invention relates to fatty amino alcohol compounds obtained by means of a process coupling, in a single step, a hydroaminomethylation reaction and a hydrohydroxymethylation reaction. 2. The compound as claimed in of formula (IIIa) in whichu is an integer between 1 and 5;{'sup': 7', '8', '9', '10, 'R, R, Rand Rrepresent a hydrogen,'}{'sup': 1', '5', '6', '1', '1, 'sub': u', 'n, 'R, R, and Rindependently of one another and, for R, independently for each of the units (CHR)represent a group of formula (II) in which A is selected independently for each of the units (A)from the groups of formula (IIa), (IIb) or (IIc),'}{'sub': n', 'n, 'the compound of formula (IIIa) comprising at least one group of formula (II) in which at least one of the units (A)is of formula (IIb), and at least one group of formula (II) in which at least one of the units (A)of formula (IIc).'}4. The compound as claimed in of formula (IIIa) in which{'sup': 7', '8', '9', '10, 'R, R, R, and Rrepresent a hydrogen and u is 1,'}{'sup': 1', '5', '6, 'R, R, and Rindependently of one another represent a group of formula (II) in which n is 1,'} [{'br': None, 'sub': 2', 'v', '2', '2', '2', 'w, 'sup': 3', '4, '—[(CH)—CH(CHNRR)—CH—(CH)]—\u2003\u2003(IIb), or'}, {'br': None, 'sub': 2', 'y', '2', '2', '2', 'z, '—[(CH)—CH(CHOH)—CH—(CH)]—\u2003\u2003(IIc);'}, {'sup': 3', '4', '3', '4, 'sub': 1', '10', '6', '12', '3', '10, 'Rand Rindependently of one another represent H, C-Calkyl, C-Caryl, benzyl, C-Ccycloalkyl, or Rand Rtogether with the nitrogen atom to which they are attached form a five- or six-membered heterocycle;'}, 'v, y, w, and z independently of one another are an integer between 4 and 9,', 'where v+w or y+z is an integer between 11 and 15,, 'A is a group of formula (IIb) or (IIc)'}the compound of formula (IIIa) comprising at ...

Lipids and Lipid Compositions for the Delivery of Active Agents

This invention provides for a compound of formula (I): 7. The compound claim 1 , or salt thereof claim 1 , according to claim 1 , wherein the compound is selected from the group consisting of:2,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl 4-(dimethylamino)butanoate;((2-(((4-(dimethylamino)butanoyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);((2-(((3-(dimethylamino)propanoyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);((2-(((1-methylpiperidine-4-carbonyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);((2-((((3-(dimethylamino)propoxy)carbonyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);((2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);3-(dimethylamino) propyl 4-methyl-2,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl carbonate;4-methyl-2,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl 4-(dimethylamino)butanoate;(9Z,9′Z,12Z,12′Z)-((2-(((4-(dimethylamino)butanoyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9,12-dienoate);4-(dimethylamino) butyl 4-methyl-2,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl carbonate;((2-(((1-ethylpiperidine-4-carbonyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);((2-(((1-isopropylpiperidine-4-carbonyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);((2-((2-(1-methylpiperidin-4-yl)acetoxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);((2-(((4-(pyrrolidin-1-yl)butanoyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);2,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl (3-(dimethylamino)propyl) carbonate;(9Z,9′Z,12Z,12′Z)-((2-(((4-(dimethylamino)butanoyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(ethane-2,1-diyl) bis(octadeca-9,12-dienoate);2,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl 3-(dimethylamino)propanoate;2,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy) ...

BRANCHED AMINO ACID SURFACTANTS

The present disclosure provides derivatives of amino acids that have branched alkyl structures and surface-active properties. The amino acid can be naturally-occurring or synthetic, or they may be obtained via a ring-opening reaction of a lactam, such as caprolactam. The amino acid may be functionalized to form a compound that is surface-active and have advantageous surfactant characteristics. The compounds of the present disclosure have low critical micelle concentrations (CMC) as well as superior ability to lower the surface tension of a liquid. 3. The compound of claim 1 , having a critical micelle concentration (CMC) of about 2.1 mmol in water.4. The compound of claim 1 , having a plateau value of a minimum surface tension of about 27 mN/m.5. The compound of claim 1 , having a surface tension in water equal to or less than 28.5 mN/m at a concentration of 1.0 mmol or greater.6. The compound of claim 1 , having a surface tension in water equal to or less than 30 mN/m at a surface age of 100 ms or greater.8. The composition of claim 7 , wherein the medium is water. This application claims priority to U.S. Provisional Application No. 63/049,744, filed Jul. 9, 2020, which is herein incorporated by reference in its entirety.The present disclosure pertains to derivatives of amino acids and methods for their synthesis, wherein the amino acid derivatives include branched alkyl structures and have surface-active properties.Surfactants (molecules with surface-active properties) are an important class of molecules with highly sought-after characteristics. Surfactants may be uncharged, zwitterionic, cationic, or anionic. Often, these compounds are amphiphilic molecules with a water-insoluble hydrophobic “tail” group and a water-soluble hydrophilic “head” group. These compounds may adsorb at an interface, such as an interface between two liquids, a liquid and a gas, or a liquid and a solid. In the case of an interface between water and oil, the hydrophilic head group extends ...

LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS

Compounds are provided having the following structure (I) or (II): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R, R, L, X, L, G, G, Z, a, aand n are independently as defined herein for each of structures (I) and (II). Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided. 2. The compound of claim 1 , wherein Gand Gare each independently —O(C═O)— or —(C═O)O—.3. The compound of or claim 1 , wherein X is CH.4. The compound of any one of - claim 1 , wherein the sum of a+b+cor the sum of a+b+cis an integer from 12 to 26.5. The compound of any one of - claim 1 , wherein aand aare independently an integer from 3 to 10.6. The compound of any one of - claim 1 , wherein aand aare independently an integer from 4 to 9.7. The compound of any one of - claim 1 , wherein band bare 0.8. The compound of any one of - claim 1 , wherein band bare 1.9. The compound of any one of - claim 1 , wherein c claim 1 , c claim 1 , dand dare independently an integer from 6 to 8.10. The compound of any one of - claim 1 , wherein R is claim 1 , at each occurrence claim 1 , independently either: (a) H or methyl; or (b) R together with the carbon atom to which it is bound is taken together with an adjacent R and the carbon atom to which it is bound to form a carbon-carbon double bond.11. The compound of any one of - claim 1 , wherein each R is H.12. The compound of any one of - claim 1 , wherein at least one R together with the carbon atom to which it is bound is taken together with an adjacent R and the carbon atom to which it is bound to form a carbon-carbon double bond.17. The compound of or claim 1 , wherein X is CH.18. The compound of any one of - claim 1 , wherein the sum of a+b+cor the sum of a+b+cis an integer from 12 to 26.19. The compound of any one of - claim 1 , wherein aand aare independently an ...

TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used. 147-. (canceled)49. The compound of claim 48 , wherein R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , and Rare H.50. The compound of claim 48 , wherein at least one of R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , and Rare is deuterium.51. The compound of claim 48 , wherein Lis —O-alkylene-C(O)—.52. The compound of claim 48 , wherein Lis —O-alkylene-OC(O)—.53. The compound of claim 48 , wherein Lis a bond.54. The compound of claim 48 , wherein the alkylene group is a C-Calkylene group.55. The compound of claim 48 , wherein the alkylene group is a Calkylene group.56. (canceled)5863-. (canceled)66. A composition comprising a compound of claim 48 , or and one or more pharmaceutically acceptable excipients.67. The composition of claim 66 , which is formulated for transdermal delivery.6870-. (canceled)71. A method of treating pulmonary hypertension claim 66 , comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of claim 66 , or or a pharmaceutically acceptable salt thereof.72. The method of claim 71 , wherein the pulmonary hypertension is pulmonary arterial hypertension.73. The method of claim 71 , wherein the compound is administered transdermally. This application claims priority to U.S. provisional application 61/751,608 filed Jan. 11, 2013 ...

ANTIMICROBIAL COMPOUNDS AND METHODS OF USE

The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions. 2. The compound of wherein{'sup': 1', '2', '3', '4', '5', '6, 'sub': 3', '3', '3', '2', '2', '6', '6', '2', '3', '2', '3', '3', '2', '2', '2', '3', '2', '2', '2', '2', '3', '2', '3, 'R, and R, are the same or different and are selected independently from the group consisting of H, CH, CHOHCH, CH(CH), CHCH, and CHCH(CH); R, and R, are the same or different and are selected independently from the group consisting of H, CH, CH(CH), CHCHOH, CHCH(CH), and (CH)N(CHCH); R, and R, are the same or different and are selected independently from the group consisting of H and CHand pharmaceutically acceptable salts thereof.'}3. The compound of wherein Ris H and Ris selected from the group consisting of CHOHCH claim 1 , CH(CH) claim 1 , CHCH claim 1 , and CHCH(CH).4. The compound of wherein Ris CHand Ris CH.5. The compound of wherein Ris H and Ris selected from the group consisting of CH(CH) claim 1 , CHCHOH claim 1 , CHCH(CH) claim 1 , and (CH)N(CHCH).6. The compound of wherein the salt is selected from the group consisting of hydrochloride claim 1 , phosphate claim 1 , maleate claim 1 , 2-hydroxypropane-1 claim 1 ,2 claim 1 ,3-tricarboxylate claim 1 , sulfonate claim 1 , methane sulfonate claim 1 , ethane sulfonate claim 1 , 2-hydroxyethane sulfonate claim 1 , benzene sulfonate claim 1 , 4-methyl- ...

ACETYLSALICYLIC ACID DERIVATIVE CRYSTAL, ITS PREPARATION METHOD AND USE

A disclosed are an acetylsalicylic acid derivative, i.e. a 2-(diethylamino)ethyl 2-acetoxy-benzoate hydrochloride crystal, and a preparation method and use thereof. The X-ray powder diffraction (XRPD) pattern of the crystal has characteristic peaks at the following 2θ angle: 11.0°±0.2°, 20.6°±0.2°, 25.1°±0.2°, 8.2°±0.2°, 16.5°±0.2°, 13.4°±0.2°, 25.4°±0.2°. 2. The method of claim 1 , wherein the indication which can be treated by acetylsalicylic acid is selected from cold and fever claim 1 , headache claim 1 , neuralgia claim 1 , muscle pain claim 1 , dysmenorrhea claim 1 , rheumatism claim 1 , rheumatoid arthritis claim 1 , gout claim 1 , cancer claim 1 , diabetes claim 1 , diabetic complications claim 1 , cardiovascular and cerebrovascular diseases claim 1 , prevention of stroke claim 1 , prevention of ischemic heart disease claim 1 , prevention of transient cerebral ischemia claim 1 , prevention of myocardial embolism claim 1 , and reduction of the incidence and mortality of arrhythmia.3. A method for preparing the 2-(diethylamino)ethyl 2-acetoxybenzoate hydrochloride crystal claim 1 , wherein the method comprises the steps of:(1) mixing a crude 2-(diethylamino)ethyl 2-acetoxybenzoate hydrochloride raw material with anhydrous acetonitrile, and completely dissolving the raw materials to obtain a solution where the final mass-volume ratio of the crude 2-(diethylamino)ethyl 2-acetoxybenzoate hydrochloride raw material to the anhydrous acetonitrile is 1: 4-1:10 w/v; and(2) cooling the solution to 0-30° C. to precipitate the 2-(diethylamino) ethyl 2-acetoxybenzoate hydrochloride crystal having a chemical structure as represented by formula I, wherein the X-ray powder diffraction (XRPD) pattern of the crystal having characteristic peaks at the following 2θ angles: 11.0°±0.2°, 20.6°±0.2°, 25.1°±0.2°, 8.2°±0.2°, 16.5°±0.2°, 13.4°±0.2°, 25.4°±0.2°.4. The method of claim 3 , wherein heating to refluxing anhydrous acetonitrile is required in the dissolution process.5. ( ...

USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE

New compound 4-[ethyl(dimethyl)ammonio]butanoate, method of preparation thereof and use in the treatment of cardiovascular disease. 2. A method of treating a cardiovascular disease in a subject in need thereof claim 1 , comprising administration of an effective amount of the 4-[Ethyl(dimethyl)ammonio]butanoate according to .3. The method according to claim 2 , wherein the cardiovascular disease is ischemic heart disease.4. The method according to claim 3 , wherein the ischemic heart disease is myocardial infarction. The present invention relates to new compound 4-[ethyl(dimethyl)ammonio]butanoate, and to a method of preparation thereof (compound of formula 5)The present invention relates also to use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease.Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels.An estimated 16.7 million—or 29.2% of total global deaths—result from the various forms of cardiovascular disease (CVD).Myocardial infarction (heart attack) is a serious result of coronary artery disease. Myocardial infarction (MI) is the irreversible necrosis of heart muscle secondary to prolonged ischemia. A heart attack or myocardial infarction is a medical emergency in which the supply of blood to the heart is suddenly and severely reduced or cut off, causing the muscle to die from lack of oxygen. More than 1.1 million people experience a heart attack (myocardial infarction) each year, and for many of them, the heart attack is their first symptom of coronary artery disease. A heart attack may be severe enough to cause death or it may be silent. As many as one out of every five people have only mild symptoms or none at all, and the heart attack may only be discovered by routine electrocardiography done some time later.A heart attack (myocardial infarction) is usually caused by a blood clot that blocks an artery of the heart. The artery has often already been narrowed by fatty deposits on its walls. ...

NEW QUATERNARY AMMONIUM COMPOUNDS

The invention concerns new quaternary ammonium compounds with surfactant properties and improved biodegradability. 2. The compound in accordance with claim 1 , wherein the compound comprises one or two groups X and two and only two groups R.3. The compound in accordance with wherein n+n′ is 1.4. The compound in accordance with wherein n+n′ is 2.5. The compound in accordance with am claim 1 , wherein n′ is 1 and Y is a C-Caliphatic group.6. The compound in accordance with claim 1 , wherein A is represented by A-6 claim 1 , m claim 1 , m′ claim 1 , m″ and m′″ are 0 claim 1 , Zto Zare O and wherein the compound comprises two groups R and one group X.7. The compound in accordance with wherein n is 0 and n′ is 1.8. The compound in accordance with wherein n is 1.9. The compound in accordance with claim 1 , wherein A is represented by A-3 or A-4 claim 1 , m claim 1 , m′ claim 1 , m″ claim 1 , m′″ and k′″ are 0 and two of substituents Qto Qare represented by groups X with both X attached to the same carbon atom of linker A and two groups R attached to the same or to different carbon atoms of linker A.10. The compound in accordance with claim 1 , wherein A is represented by A-1 claim 1 , m and m′ are 1 claim 1 , m″ and m′″ are 0 claim 1 , k is 0 and two substituents Qto Qare represented by groups X with both groups X being attached to the —(CH)and —(CH)′— groups directly attached to the nitrogen atom of linker A.11. The compound in accordance with claim 1 , wherein A is represented by A-2 claim 1 , k′ is 0 claim 1 , k″ is 1 claim 1 , m is 1 claim 1 , m′ claim 1 , m″ and m′″ are 0 and two of substituents Qto Qare represented by groups X attached to two adjacent carbon atoms of linker A.12. The compound in accordance with claim 1 , wherein A is represented by A-5 claim 1 , m claim 1 , m′ claim 1 , m″ claim 1 , m′″ and k″″ are 0 claim 1 , two of substituents Qto Qare X with each carbon atom of linker A carrying one group X and one group R wherein X and R might be the same or ...

PROCESS FOR MAKING SOLID METHYLGLYCINE DIACETATE (MGDA) ALKALI METAL SALT, AND SOLID PARTICLES

A process for making solid methylglycine diacetate (MGDA) alkali metal salt (a) includes: 1. Process for making solid methylglycine diacetate (MGDA) alkali metal salt (a) , said process comprising the steps of(A) providing a 40 to 60% by weight aqueous solution of said MGDA salt having a temperature in the range of from 50 to 90° C.,(B) adding solid salt (a),(C) heating the resultant slurry until the salt (a) added in step (B) has dissolved at least partially,(D) allowing salt (a) to crystallize, and(E) removing crystalline salt (a) from the mother liquor.2. The process according to claim 1 , wherein in step (C) claim 1 , the resultant slurry is heated until a clear solution is obtained.3. The process according to claim 1 , wherein step (E) is carried out by filtration or with the help of a centrifuge.5. The process according to wherein in step (D) the temperature is decreased by 20 to 90° C.6. The process according to wherein in the salt (a) claim 1 , the L-enantiomer is present by an enantiomeric excess in the range of from zero to 40%.7. The process according to wherein said process comprises an additional step of adding mother liquor from step (D) in whole or in part to an aqueous solution of methylglycine diacetate (MGDA) alkali metal salt (a) and adjusting its concentration to 35 to 60% by weight.8. The process according to wherein between steps (C) and (D) claim 1 , seed crystals of the salt (a) are added. The present invention relates to a process for making solid methylglycine diacetate (MGDA) alkali metal salt (a), said process comprising the steps ofIn addition, the present invention relates to solid particles comprising a salt of MGDA.Chelating agents such as methyl glycine diacetic acid (MGDA) and their respective alkali metal salts are useful sequestrants for alkaline earth metal ions such as Ca and Mg. For that reason, they are recommended and used for various purposes such as laundry detergents and for automatic dishwashing (ADW) formulations, in ...

COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression. 2. The ionizable lipid of claim 1 , wherein the salt is a pharmaceutically acceptable salt.3. A nanoparticle composition comprising a lipid component comprising an ionizable lipid of .4. The nanoparticle composition of claim 3 , wherein the lipid component further comprises a phospholipid.5. The nanoparticle composition of claim 4 , wherein the phospholipid is selected from the group consisting of 1 claim 4 ,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC) claim 4 ,1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC),1-hexadecyl-sn-glycero-3-phosphocholine (C 16 Lyso PC),1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine,1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE),1,2-distearoyl-sn-glycero-3-phosphoethanolamine,1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine,1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) ...

METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS

A lipid particle can include a cationic lipid. The cationic lipid can include one or more hydrophobic tails, which can include one or more sites of unsaturation. The sites of unsaturation can include cycloalkyl groups, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl groups. The lipid particle is suitable for delivering an active agent. 5. (canceled)6. The cationic lipid of claim 1 , wherein -L-(CRR)— is —(CH)—.9. The cationic lipid of claim 7 , wherein L-Ris —(CH)—CHor —CH.10. The cationic lipid of claim 1 , wherein Rand Rare free of carbon-carbon double-bonds.11. (canceled)12. The cationic lipid of claim 1 , wherein Hdhas the formula —X—(CRR)—N(R)(R)(R) claim 1 , Hdis H claim 1 , X is O claim 1 , and Ris absent claim 1 , and Rand Rare each independently alkyl optionally substituted by halo; hydroxy; cyano; oxo; nitro; C-Ccycloalkyl optionally substituted by halo claim 1 , hydroxy claim 1 , or alkoxy; aryl; heteroaryl; or heterocyclyl.1314-. (canceled)1620-. (canceled)21. A lipid particle comprising a neutral lipid claim 1 , a lipid capable of reducing aggregation claim 1 , and a cationic lipid of .22. The lipid particle of claim 21 , wherein the neutral lipid is selected from DSPC claim 21 , DPPC claim 21 , POPC claim 21 , DOPE claim 21 , and SM; the lipid capable of reducing aggregation is a PEG lipid; and the lipid particle further comprises a sterol claim 21 , wherein the cationic lipid is present in a molar ratio of about 20% and about 60%; the neutral lipid is present in a molar ratio of about 5% to about 25%; the sterol is present in a molar ratio of about 25% to about 55%; and the PEG lipid is PEG-DMA claim 21 , PEG-DMG claim 21 , or a combination thereof claim 21 , and is present in a molar ratio of about 0.5% to about 15%.23. (canceled)24. The lipid particle of claim 21 , further comprising an active agent claim 21 , wherein the active agent is a nucleic acid selected from the group consisting of a plasmid claim 21 , an immunostimulatory ...

NOVEL LIPID

The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient. 2. The cationic lipid of or a pharmacologically acceptable salt thereof claim 1 , wherein Rand Rare each independently a C-Calkyl group optionally substituted with one or more substituents selected from substituent group α.3. The cationic lipid of or a pharmacologically acceptable salt thereof claim 1 , wherein Rand Rare each independently a C-Calkyl group.4. The cationic lipid of or a pharmacologically acceptable salt thereof claim 1 , wherein both Rand Rare methyl groups.5. The cationic lipid of or a pharmacologically acceptable salt thereof claim 1 , wherein Rand Rform azetidine claim 1 , pyrrolidine claim 1 , piperidine claim 1 , azepane claim 1 , dihydropyrrole claim 1 , dihydropyridine claim 1 , tetrahydropyridine claim 1 , piperazine claim 1 , morpholine claim 1 , dihydrooxazole claim 1 , or dihydrothiazole optionally substituted with one or more substituents selected from substituent group α claim 1 , together with the nitrogen atom bonded thereto.6. The cationic lipid of or a pharmacologically acceptable salt thereof claim 1 , wherein Rand Rform azetidine claim 1 , pyrrolidine claim 1 , piperidine claim 1 , or morpholine optionally substituted with one or more substituents selected from substituent group α claim 1 , together with the nitrogen atom bonded thereto.7. The cationic lipid of or a pharmacologically acceptable salt thereof claim 1 , wherein Rand Rform azetidine claim 1 , pyrrolidine claim 1 , or morpholine together with the nitrogen atom bonded thereto.8. The cationic lipid of or a pharmacologically acceptable salt thereof claim 1 , wherein{'sup': 1', '8, 'sub': 2', ...

NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids comprising at least one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA. 2. A cationic lipid of Formula A according to claim 1 , wherein:{'sup': 1', '2, 'Rand Rare each methyl;'}{'sup': '3', 'Ris H;'}n is 3;X is (C═O)O;{'sub': 1', '4', '24', '4', '24, 'Lis selected from C-Calkyl and C-Calkenyl; and'}{'sub': 2', '3', '9', '3', '9, 'Lis selected from C-Calkyl and C-Calkenyl;'}or any pharmaceutically acceptable salt or stereoisomer thereof.3. A cationic lipid which is:(20Z,23Z)-nonacosa-20,23-dien-10-yl 4-(dimethylamino)butanoate (Compound 1); and(18Z)-heptacos-18-en-10-yl 4-(dimethylamino)butanoate (Compound 2);or any pharmaceutically acceptable salt or stereoisomer thereof.4. The use of a cationic lipid according to for the preparation of lipid nanoparticles.5. The use of a cationic lipid according to as a component in a lipid nanoparticle for the delivery of oligonucleotides.6. The use according to wherein the oligonucleotides are siRNA or miRNA.7. The use according to wherein the oligonucleotides are siRNA. The present invention relates to novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides, to facilitate the cellular uptake and endosomal escape, and to knockdown target mRNA both in vitro and in vivo.Cationic lipids and the use of cationic lipids in lipid nanoparticles for the delivery of oligonucleotides, in particular siRNA and miRNA, have been ...

Lipids and Lipid Compositions for the Delivery of Active Agents

This invention provides for a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R, R, Rand Rare defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues. 7. The compound claim 1 , or salt thereof claim 1 , according to claim 1 , wherein the compound is selected from the group consisting of:2,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl 4-(dimethylamino)butanoate;((2-(((4-(dimethylamino)butanoyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);((2-(((3-(dimethylamino)propanoyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);((2-(((1-methylpiperidine-4-carbonyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);((2-((((3-(dimethylamino)propoxy)carbonyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);((2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);3-(dimethylamino)propyl 4-methyl-2,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl carbonate;4-methyl-2,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl 4-(dimethylamino)butanoate;(9Z,9′Z,12Z,12′Z)-((2-(((4-(dimethylamino)butanoyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9,12-dienoate);4-(dimethylamino)butyl 4-methyl-2,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl carbonate;((2-(((1-ethylpiperidine-4-carbonyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);((2-(((1-isopropylpiperidine-4-carbonyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);((2-((2-(1-methylpiperidin-4-yl)acetoxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);((2-(((4-(pyrrolidin-1-yl)butanoyl)oxy)methyl)-1,4-phenylene)bis(oxy))bis(octane-8,1-diyl) bis(decanoate);2,5-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)benzyl (3-(dimethylamino)propyl) carbonate;(9Z, ...

METHOD FOR PRODUCING CATIONIC SURFACTANT

The present invention provides a method for producing a high quality cationic surfactant, which is prevented from smelling and coloring, and has favorable storage stability. 1. A method for producing a cationic surfactant comprising the following step 1 , step 2 , step 3 , and step 4:step 1: a step of obtaining an alkanolamine ester by reacting an alkanolamine with a fatty acid or a fatty acid alkyl ester without using hypophosphoric acid or a salt thereof;step 2: a step of obtaining a cationic surfactant by quaternizing the alkanolamine ester obtained in the step 1 with a dialkyl sulfate;step 3: a step of performing an oxidation treatment of the cationic surfactant obtained in the step 2; andstep 4: a step of performing a reduction treatment of the cationic surfactant subjected to the oxidation treatment obtained in the step 3.2. The method for producing a cationic surfactant according to claim 1 , wherein the oxidation treatment in the step 3 is a treatment in which the cationic surfactant and an oxidizing agent are mixed with each other claim 1 , and the using amount of the oxidizing agent is 0.001 parts by mass or more and 1.0 parts by mass or less with respect to 100 parts by mass of the cationic surfactant obtained in the step 2.3. The method for producing a cationic surfactant according to claim 2 , wherein the oxidizing agent is one or more selected from chlorous acid claim 2 , hypochlorous acid claim 2 , and alkali metal salts thereof.4. The method for producing a cationic surfactant according to claim 1 , wherein the reduction treatment in the step 4 is a treatment in which the cationic surfactant and a reducing agent are mixed with each other claim 1 , the reducing agent is hypophosphoric acid or an alkali metal salt thereof claim 1 , and the using amount of the reducing agent is 0.001 parts by mass or more and 1.0 parts by mass or less with respect to 100 parts by mass of the cationic surfactant obtained in the step 2.5. The method for producing a ...

TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used. 170-. (canceled)72. The compound of claim 71 , wherein Ris Pand Ris H.73. The compound of claim 71 , wherein Ris H and Ris P.74. The compound of claim 71 , wherein Ris Pand Ris P.75. The compound of claim 71 , wherein each of Rto Ris H.76. The compound of claim 71 , wherein at least one of Rto Ris deuterium.77. The compound of claim 71 , wherein Z is —OR.78. The compound of claim 71 , wherein Z is P.79. The compound of claim 71 , wherein Z is —N(R)R.80. The compound of claim 71 , wherein Z is —OH.82. A composition comprising a compound of or a pharmaceutically acceptable salt thereof and at least one other component.83. The composition of claim 82 , which is formulated for transdermal delivery.84. The composition of claim 83 , which is formulated for transdermal delivery with a patch.85. The composition of claim 82 , further comprising at least one solvent.86. A method of treating pulmonary hypertension claim 71 , comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt thereof.87. The method of claim 86 , wherein the pulmonary hypertension is pulmonary arterial hypertension.88. The method of claim 86 , wherein the compound is administered transdermally.89. The method of claim 88 , wherein the compound is administered via a transdermal patch. This application claims priority to U.S. provisional application 61/751,608 filed Jan. 11, 2013 which is incorporated herein by reference in its entirety for all purposes.Pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH) is a disease which can result in death and is ...

ACETYLSALICYLIC ACID DERIVATIVE CRYSTAL, ITS PREPARATION METHOD AND USE

Disclosed are an acetylsalicylic acid derivative, i.e. a 2-(diethylamino)ethyl 2-acetoxy-benzoate hydrochloride crystal, and a preparation method and use thereof. The X-ray powder diffraction (XRPD) pattern of the crystal has characteristic peaks at the following 2θ angle: 11.0°±0.2°, 20.6°±0.2°, 25.1°±0.2°, 8.2°±0.2°, 16.5°±0.2°, 13.4°±0.2°, 25.4°±0.2°. 2. The crystal of claim 1 , wherein the X-ray powder diffraction (XRPD) pattern of the crystal further having a characteristic peak at the following 2θ angle: 10.8°±0.2°.3. The crystal of claim 1 , wherein the X-ray powder diffraction (XRPD) pattern of the crystal further having characteristic peaks at the following 2θ angles: 22.8°±0.2° claim 1 , 30.4°±0.2° claim 1 , 19.2°±0.2° claim 1 , 17.6°±0.2° claim 1 , 10.6°±0.2° claim 1 , 23.0°±0.2° claim 1 , 35.7°±0.2° claim 1 , 27.9°±0.2° claim 1 , 18.2°±0.2° claim 1 , 24.8°±0.2° claim 1 , 22.1°±0.2°.4. The crystal of claim 1 , wherein the infrared absorption spectrum of the crystal having absorption peaks at 2988.0 cm claim 1 , 2974.6 cm claim 1 , 2953.7 cm claim 1 , 2889.1 cm claim 1 , 1725.9 cm claim 1 , 1759.1 cm claim 1 , 1605.6 cm claim 1 , 1576.1 cm claim 1 , 1484.0 cm claim 1 , 1448.2 cm claim 1 , 1389.9 cm claim 1 , 1068.7 cm claim 1 , 1087.1 cm claim 1 , 757.0 cm claim 1 , and in a range of 2487.3 cmto 2563.4 cm.6. The crystal of claim 5 , wherein the crystal further comprises the following characteristics claim 5 , as determined by X-ray single crystal diffraction:a crystallographic space group: Pbca;{'sup': 3', '3, 'a unit lattice volume: V=3311.4 ű1.0 Å;'}{'sup': '3', 'a crystal size: 0.211×0.176×0.112 mm;'}{'sup': '3', 'a crystal density: 1.267 mg/m;'}a number of asymmetrical units in lattice: 8; anda number of electrons in a unit cell: F(0000)=1344.7. A method for preparing the 2-(diethylamino)ethyl 2-acetoxybenzoate hydrochloride crystal of claim 1 , wherein the method comprises the steps of:(1) mixing a crude 2-(diethylamino)ethyl 2-acetoxybenzoate ...

CARBOXYBETAINE-FUNCTIONALIZED DIOLS

A compound having the formula: XN(CH)(CHCHOH)[(CH)—COO—R]. Ris an ester protecting group, X is a halide, and n is a positive integer. A method of reacting N-methyldiethanolamine with an ω-halo-n-alkanoate ester to form the compound. 1. A compound having the formula:{'br': None, 'sup': −', '+', '1, 'sub': 3', '2', '2', '2', '2', 'n, 'XN(CH)(CHCHOH)[(CH)—COO—R];'}wherein n is a positive integer greater than 2;{'sup': '−', 'wherein X is a halide; and'}{'sup': '1', 'wherein Ris an ester protecting group.'}24-. (canceled)5. The compound of claim 1 , wherein X is Br.6. The compound of claim 1 , wherein Ris CHCH.7. A method comprising: {'br': None, 'sup': −', '+', '1, 'sub': 3', '2', '2', '2', '2', 'n, 'XN(CH)(CHCHOH)[(CH)—COO—R];'}, 'reacting N-methyldiethanolamine with an ω-halo-n-alkanoate ester to form a compound having the formulawherein n is a positive integer greater than 2;{'sup': '−', 'wherein X is a halide; and'}{'sup': '1', 'wherein Ris an ester protecting group.'}810-. (canceled)11. The method of claim 7 , wherein X is Br.12. The method of claim 7 , wherein Ris CHCH.13. A compound having the formula:{'br': None, 'sup': −', '+, 'sub': 3', '2', '2', '2', '2', 'n', '2', '3, 'XN(CH)(CHCHOH)[(CH)—COO—CHCH];'}wherein n is a positive integer; and{'sup': '−', 'wherein X is a halide.'}14. The compound of claim 13 , wherein n is from 1 to 5.15. The compound of claim 13 , wherein n is 1 claim 13 , 3 claim 13 , 4 claim 13 , or 5.16. The compound of claim 13 , wherein n is greater than 2.17. The compound of claim 13 , wherein X is Br.18. A method comprising: {'br': None, 'sup': −', '+, 'sub': 3', '2', '2', '2', '2', 'n', '2', '3, 'XN(CH)(CHCHOH)[(CH)—COO—CHCH];'}, 'reacting N-methyldiethanolamine with an ethyl ω-halo-n-alkanoate ester to form a compound having the formulawherein n is a positive integer; and{'sup': '−', 'wherein X is a halide.'}19. The method of claim 18 , wherein n is from 1 to 5.20. The method of claim 18 , wherein n is 1 claim 18 , 3 claim 18 , 4 claim 18 ...

TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used. 170-. (canceled)72. The compound of claim 71 , wherein Ris Pand Ris H.73. The compound of claim 71 , wherein Ris H and Ris P.74. The compound of claim 71 , wherein Ris Pand Ris P.75. The compound of claim 71 , wherein each of Rto Ris H.76. The compound of claim 71 , wherein at least one of Rto Ris deuterium.77. The compound of claim 71 , wherein Z is —OR.78. The compound of claim 71 , wherein Z is P.79. The compound of claim 71 , wherein Z is —N(R)R.80. The compound of claim 71 , wherein Z is −OH.82. A composition comprising a compound of or a pharmaceutically acceptable salt thereof and at least one other component.83. The composition of claim 82 , which is formulated for transdermal delivery.84. The composition of claim 83 , which is formulated for transdermal delivery with a patch.85. The composition of claim 82 , further comprising at least one solvent.86. A method of treating pulmonary hypertension claim 71 , comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt thereof.87. The method of claim 86 , wherein the pulmonary hypertension is pulmonary arterial hypertension.88. The method of claim 86 , wherein the compound is administered transdermally.89. The method of claim 88 , wherein the compound is administered via a transdermal patch. This application claims priority to U.S. provisional application 61/751,608 filed Jan. 11, 2013 which is incorporated herein by reference in its entirety for all purposes.Pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH) is a disease which can result in death and is ...

Fatty amine derivatives of butylated hydroxy toluene for the protection of surfaces from physical and chemical degradation

The present invention relates to novel antioxidant compounds to reduce the physical or chemical degradation or discoloration of surfaces, especially the fading of a variety of surfaces from sunlight, wherein the antioxidant compound is a derivative of butylated hydroxytoluene or sorbic acid and is selected from the group consisting of: (I), (II), (III), (IV), wherein each R?1 and R3¿ is selected from the group consising of hydroxy, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, propyl, straight or branched chained butyl groups, straight or branched chained amyl groups, and mixtures thereof; R2 is a hydroxy group; each R?4 and R7¿ is selected from the group consisting of a saturated or unsaturated C¿1?-C22, alkyl, aryl, cyclic alkyl group (which may be interrupted by an ester, amide, or ether group), hydrogen, and mixtures thereof; each R?5, R6, R8, and R9¿ is selected from the group consising of a saturated or unsaturated C¿1?-C22, alkyl, aryl, cyclic alkyl group (which may be interrupted by an ester, amide, or ether group), and mixtures thereof; n is from 1 to 50; Y is a hydrogen or a methyl group; Z is a hydrogen or a methyl group; wherein the amino group of the compounds of formulas (I) to (IV) can be protonated or quaternized with R?10¿X where R10 is a hydrogen, a C¿1?-C6 alkyl group, C1-C6 hydroxyl alkyl group, benzyl group and mixtures thereof; and X?-¿ is any compatible anion.

Unsymmetrical dicarboxylic esters as bleach precursors

A bleach precursor compound, its peroxygen derivative, and detergent compositions containing these materials are disclosed herein. The bleach precursors structurally comprise a pair of different diesters, one ester containing an electrically-charged functional group. Perhydrolysis of the precursor in the presence of hydrogen peroxide and a basic aqueous media generates a peroxycarboxylic acid.

Polymers

디아미노카르보네이트 화합물 및 그것을 촉매로서 사용하는 방법(diaminocarbonate compounds and their use as catalysts)

Bio-based dispersants.

La presente invención proporciona un nuevo dispersante de base biológica que comprende el producto de reacción de un aceite triglicerídico natural, aceite de ácido graso o derivado de ácido graso, en donde el aceite triglicerídico natural, aceite de ácido graso o derivado de ácido graso contiene más de aproximadamente 80 por ciento de ácidos grasos insaturados o conjugados insaturados con un sustrato capaz de experimentar una reacción eno o Diels Alder para formar un aducto que se esterifica y/o neutraliza adicionalmente con una alcanolamina o alcanolamina alcoxilada.

Novel polycation compound and bleach composition containing the same

Diaminocarbonate compounds and their use as catalysts

본 발명은 고형 또는 기포질 우레탄 및/또는 우레아 중합체의 제조시 특히 저-냄새 촉매로서 사용하기에 적당한 디아미노카르보네이트 화합물에 관한 것이다. 그러한 화합물은 아미노 알콜과 알킬 카르보네이트를 반응시키므로써 제조할 수 있다. The present invention relates to diaminocarbonate compounds which are particularly suitable for use as low-odor catalysts in the preparation of solid or foamed urethane and / or urea polymers. Such compounds can be prepared by reacting amino alcohols with alkyl carbonates.

Lipids and lipid compositions for the delivery of active agents

This invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 -R 3 , n, p, L 1 and L 2 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Novel quaternary ammonium compounds

本发明涉及具有表面活性剂特性和改善的生物降解性的新的季铵化合物。

Bleach precursors

PROCESS FOR THE PREPARATION OF THE ENANTIOMERIC FORMS OF AMINO ALKYLAMINOPHENYLPROPANOIC ACID

Fatty amine derivatives of butylated hydroxy toluene for the protection of surfaces from physical and chemical degradation

The present invention relates to non-surface staining, light stable antioxidant compounds which reduce the fading, decoloration and degradation of various surfaces, ie., fabrics, from sunlight. These antioxidant compounds are butylated hydroxytoluene and sorbic acid derivatives, containing at least one C 8 -C 22 hydrocarbon fatty amine organic moiety and are either solid materials having a melting point of less than about 80° Celsius, or are liquids at a temperature of less than about 40° Celsius.

Automatic dishwashing compositions comprising multiperacid-forming bleach activators

Improved automatic dishwashing detergent compositions, especially granular detergents, comprising bleach activators which form multiperacids, especially specific monoquaternary substituted bis(peroxycarbonic) acids, upon perhydrolysis are provided.

Aminocarbonate compounds and their use as catalyst

Det blir beskrevet amlnokarbonatforbindelser som spesielt er egnet som luktløse katalysatorer for fremstilling av massive eller celleformlge uretan- og/eller urlnstoffpolymerer. Disse forbindelsene kan fremstilles ved omsetning av amlnoalkoholer med alkylkarbonater.

Diaminocarbonate compounds and their use as catalysts

The invention concerns diaminocarbonate compounds which are suitable in particular for use as low-odour catalysts in the production of solid or cellular urethane and/or urea polymers. Such compounds may prepared by reacting aminoalcohols with alkycarbonates.

Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents

The application relates to lipids of the general Formula (A) wherein at least one of the two side chains contains a carbonate functional group (M and/or M' is -0C(=0)0-) and to empty or loaded lipid nanoparticles (LNPs) including such lipids as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

Nopimic acid derivatives their preparation and pharmaceutical compositions containing them

Beta-pinene derivatives and their preparation

Machine dishwashing detergent compositions containing bleach activators which form polybasic percarboxylic acids

Detergent compositions

The present invention relates to cationic compounds and their application in detergent compositions. The compounds have the dual benefits of surfactancy and of suds suppression.

HERBICIDAL AGENT

Bio-based dispersants

The invention provides a novel bio-based dispersant comprising the reaction product of a natural triglyceridic oil, fatty acid oil or fatty acid oil derivative wherein said natural triglyceridic oil, fatty acid oil, or fatty acid oil derivative containing greater than about 80 percent of unsaturated or conjugated unsaturated fatty acids with a substrate capable of undergoing an ene or Diels Alder reaction to form an adduct that is further esterified and/or neutralized with an alkanolamine or alkoxylated alkanolamine.

Herbicide composition

1430548 Substituted aniline derivatives VELSICOL CHEMICAL CORP 27 June 1974 [30 July 1973] 28526/74 Heading C2C [Also in Division A5] Compounds of a general formula in which X is alkyl ; t is an integer from 0 to 3; and Y is a straight or branched alkylene chain of from 2 to 3 carbon atoms are prepared by reacting a molar amount of compound of a general formula with two molar amounts of 2-methoxy-3,6- dichlorobenzoyl chloride. The compounds have herbicidal properties.

A kind of tetracyclic diterpene class iso steviol compound and preparation method and application

本发明公开了一种四环二萜类异斯特维醇化合物及其制备方法与应用，属药物化学领域。该类化合物含有α‑亚甲基环戊酮结构片段，结构如式1所示，其季铵盐如式2所示。其在抑制人食管癌细胞株Ec109、人胃癌细胞株MGC803和人前列腺癌细胞株PC‑3方面具有较好的活性。式中，n＝1‑6。

Method for producing cationic surfactant

The present invention provides a method for producing a high quality cationic surfactant, which is prevented from smelling and coloring, and has favorable storage stability. The production method includes the following step 1, step 2, step 3, and step 4: step 1: a step of obtaining an alkanolamine ester by reacting an alkanolamine with a fatty acid or a fatty acid alkyl ester without using hypophosphoric acid or a salt thereof; step 2 : a step of obtaining a cationic surfactant by quaternizing the alkanolamine ester obtained in the step 1 with a dialkyl sulfate; step 3 : a step of performing an oxidation treatment of the cationic surfactant obtained in the step 2; and step 4 : a step of performing a reduction treatment of the cationic surfactant subjected to the oxidation treatment obtained in the step 3.

Nanomaterials

Lipid nanoparticle compositions for delivery of nucleic acids are described. The lipid nanoparticle may contain a conformationally constrained ionizable lipid as part of the composition. These compositions may allow for delivery of cargo without the need for a targeting ligand.

FOERFARANDE FOER FRAMSTAELLNING AV 2-DIETYLAMINO-1-METYLETYLESTRAR AV SUBSTITUERADE HYDROXICYKLOHEKSANKARBOXYLSYROR

Adamantane tail chain lipid and application thereof in cell transfection

本发明公开了金刚烷尾链脂质及其在细胞转染中的应用。本发明公开一类金刚烷尾链脂质，选取尺寸较小的叔胺作为亲水头基，酯键作为连接键，金刚烷乙酸和直链烷烃作为疏水尾链。一方面利用烷烃链与细胞膜的高度亲和力有利于LNP跨越细胞膜，另一方面借助金刚烷尾链脂质能够显著减小LNP粒径的以提高细胞的摄取量，从而增强转染效果。本发明的金刚烷尾链脂质及其制备的LNP安全性良好，对原代免疫细胞或肿瘤细胞均具有较好的转染能力，在一定程度上解决了目前非病毒载体对细胞转染效率低下的问题，对于开发具有我国自主知识产权的生物功能载体材料具有重要意义。

Process for preparing enantiomeric forms of aminoalkylaminophenylpropanoic acid

A method for preparing an enantiomeric form of 2-amino-3-(4-alkylaminophenyl)propanoic acid of general formula (I), wherein Alk is a C1-2 alkyl radical in (S) or (R) form, and salts thereof, from (L)-phenylalanine and (D)-phenylalanine respectively, by nitration followed by conversion of the nitro radical of the resulting 4-nitro phenylalanine of general formula (II), wherein R is a hydrogen atom or a protective radical, into an alkylamino radical, optionally after having protected the amine function of the phenylalanine.

Benzocyclobutene carboxylate esters.

A kind of amphiphilic calixarenes AmC5A nano supermolecule assembly and its preparation method and application

一种两亲杯芳烃AmC5A的纳米超分子组装体，其构筑单元的化学式为C 125 H 210 N 5 O 15 5+ ，超分子组装体的构筑是通过弱的π–π相互作用，疏水相互作用，其形貌尺度为纳米级、球形的囊泡；以两亲杯芳烃AmC5A纳米超分子组装体作为组装体囊泡，选择性的在囊泡外层表面和疏水层包结不同的荧光分子，通过荧光分子的能量传递现不同的荧光颜色。本发明的优点是：以胆碱修饰两亲杯芳烃AmC5A作为构筑单元，在AmC5A的临界聚集浓度之上形成囊泡，不但在实现荧光分子有组织排布的同时克服了荧光分子之间的自淬灭，还可利用超分子的特性任意的调整荧光分子的种类和比例，实现了对其发光性质的精确调控。

AMINOCARBONATE COMPOUNDS AND THEIR USE AS CATALYSTS

Amine salts of nopinic acid

Novel compounds of the formulae <FORM:1117782/C2/1> <FORM:1117782/C2/2> (wherein X1 is an ammonium cation, a C1- 4 alkyl radical or the group -(CH2)n-NRR1 in which n is 1, 2 or 3 and R and R1 are each hydrogen or C1- 4 alkyl) and acid-addition salts of the amino-esters are prepared (1) by reaction of nopinic acid with ammonia to give ammonium nopinate (2) by esterification of nopinic acid or transesterification of its alkyl esters with alkanols or aminoalkanols to give corresponding esters of nopinic acid, or by reaction of alkali metal salts of nopinic acid with alkyl halides or aminoalkyl halides and (3) by mixing nopinic acid and amino-alkanols in suitable solvents to give salts of nopinic acid with the amino-alkanols. Examples are given. The novel nopinic acid derivatives may be made up into pharmaceutical compositions for the prevention and control of ulcers and/or of pain due to ulcers. The compositions may be for peroral, topical or parentaral use.

Dicarboxylic salts of polyhydroxy tertiary amines

PROCEDURE FOR PREPARING THE ENANTIOMER FORMS OF AMINO ALKYLAMINOPHENYL PROPANIC ACID.

Procedimiento para preparar una forma enantiómera del ácido amino-2 (alquilamino-4 fenil)-3 propanoico de fórmula general (I) en la que Alkrepresenta un radical alcoilo que contiene 1 ó 2 átomos de carbono, en forma (S) ó (R), como tambiénla preparación de sus sales, a partir de la (L)-fenilanina o de la (D)-fenilalanina, respectivamente por nitración seguida por la transformación del radical nitro de la nitro-4 fenilalanina obtenida, defórmula general (II), en la cual R es un átomode hidrógeno o un radical protector, en un radical alcoílamino, dado el caso después de la protección dela función amina de la fenilalanina. Process for preparing an enantiomeric form of amino-2 (alkylamino-4-phenyl) -3 propanoic acid of general formula (I) in which Alk represents an alkoyl radical containing 1 or 2 carbon atoms, in form (S) or (R ), as well as the preparation of its salts, from (L) -phenylalanine or (D) -phenylalanine, respectively by nitration followed by the transformation of the nitro radical of the nitro-4-phenylalanine obtained, of the general formula (II) in which R is a hydrogen atom or a protective radical, in an alkoylamino radical, optionally after protection of the amine function of phenylalanine.

A kind of worm micella formed by abietyl Gemini surface active agent

本发明公开了一种由松香基双子表面活性剂形成的蠕虫胶束，属于天然产物表面活性剂的合成与应用领域。本发明的松香基双子表面活性剂的分子结构如下： 本发明给出了这种松香基双子表面活性剂的合成方法及蠕虫胶束的制备方法。该松香基双子表面活性剂的相对分子质量为1071.26，其临界胶束浓度值为0.1009mmol·L ‑1 ，具有较好的水溶性。当其溶液浓度大于50mmol·L ‑1 时，自身可形成蠕虫状胶束。作为一种绿色环保的表面活性剂，可应用于日用化学品配方及石油开采等工业过程。

Mono-2-[dodecyl-(2-hydroxyethyl)amino]ethyl dicarboxylates, their salts and their use as corrosion inhibitors in aqueous systems

The invention relates to mono-2-[dodecyl-(2-hydroxyethyl)amino]ethyl dicarboxylates of the general formula (I) <IMAGE> and their salts of the general formula (II) <IMAGE> in which A stands for the radicals <IMAGE> and M stands for an alkali metal or the ammonium group, and the use of compounds of this type on their own or in combination with one or more complexing agents in concentrations of 10 to 250 g/m<3> as corrosion inhibitors in aqueous systems, if appropriate in the presence of further scale inhibitors and/or dispersing agents and/or non-ferrous metal inhibitors and/or microbicides known per se.

N,n-bis(3,6-dichloro-2-methoxybenzoyloxyalkyl) anilines

N, N-BIS (2-METHOXY-3,6-DICHLOROBENZOYLOXIALKYL) -ANILINS FOR HERBICIDA ENDAMAL

Patent FR2442225B1

FATTY AMINOALCOOLS AND PROCESS FOR PREPARING THE SAME

La présente invention se rapporte à des composés aminoalcool et à la préparation de ceux-ci à partir d'esters gras comprenant au moins deux doubles liaisons carbone-carbone . En particulier, la présente invention concerne des composés aminoalcool gras obtenus par un procédé couplant en une seule étape une réaction d'hydroaminométhylation et une réaction d'hydrohydroxyméthylation. The present invention relates to aminoalcohol compounds and to the preparation thereof from fatty esters comprising at least two carbon-carbon double bonds. In particular, the present invention relates to fatty amino-alcohol compounds obtained by a process that couples in one step a hydroaminomethylation reaction and a hydrohydroxymethylation reaction.

Fatty amine derivatives of butylated hydroxy toluene for the protection of surfaces from physical and chemical degradation

The present invention relates to novel antioxidant compounds to reduce the physical or chemical degradation or discoloration of surfaces, especially the fading of a variety of surfaces from sunlight, wherein the antioxidant compound is a derivative of butylated hydroxytoluene or sorbic acid and is selected from the group consisting of: (I), (II), (III), (IV), wherein each R1 and R3 is selected from the group consising of hydroxy, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, propyl, straight or branched chained butyl groups, straight or branched chained amyl groups, and mixtures thereof; R2 is a hydroxy group; each R4 and R7 is selected from the group consisting of a saturated or unsaturated C1-C22, alkyl, aryl, cyclic alkyl group (which may be interrupted by an ester, amide, or ether group), hydrogen, and mixtures thereof; each R5, R6, R8, and R9 is selected from the group consising of a saturated or unsaturated C1-C22, alkyl, aryl, cyclic alkyl group (which may be interrupted by an ester, amide, or ether group), and mixtures thereof; n is from 1 to 50; Y is a hydrogen or a methyl group; Z is a hydrogen or a methyl group; wherein the amino group of the compounds of formulas (I) to (IV) can be protonated or quaternized with R10X where R10 is a hydrogen, a C1-C6 alkyl group, C1-C6 hydroxyl alkyl group, benzyl group and mixtures thereof; and Xis any compatible anion.

Fatty amino alcohols and process for preparing same

The present invention relates to amino alcohol compounds and to the preparation thereof from fatty esters comprising at least two carbon-carbon double bonds. In particular, the present invention relates to fatty amino alcohol compounds obtained by means of a process coupling, in a single step, a hydroaminomethylation reaction and a hydrohydroxymethylation reaction.

PROCESS FOR PREPARING BASIC ESTERS OF SUBSTITUTED HYDROXYCYCLOHEXANE CARBONIC ACIDS.

BUTYLATED HYDROXYTOLUENE FAT AMINE DERIVATIVES FOR THE PROTECTION OF SURFACES AGAINST PHYSICAL AND CHEMICAL DEGRADATION.

LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS ANTIOXIDANTES PARA REDUCIR LA DEGRADACION O DECOLORACION FISICA O QUIMICA DE SUPERFICIES, ESPECIALMENTE LA DECOLORACION DE UNA VARIEDAD DE SUPERFICIES POR LA LUZ SOLAR, EN DONDE EL COMPUESTO ANTIOXIDANTE ES UN DERIVADO DE HIDROXITOLUENO BUTILADO O DE ACIDO SORBICO Y SE SELECCIONA DEL GRUPO QUE CONSTA DE: (I), (II), (III), (IV), EN DONDE CADA R{SUP,1} Y R{SUP,3} SE SELECCIONA DEL GRUPO QUE CONSTA DE HIDROXIDO, METOXI, ETOXI, PROPOXI, BUTOXI, METILO, ETILO, PROPILO, GRUPOS DE BUTILO DE CADENA RECTA O RAMIFICADA, GRUPOS DE AMILO DE CADENA RECTA O RAMIFICADA, Y MEZCLAS DE LOS MISMOS; R{SUP,2} ES UN GRUPO HIDROXIDO; CADA R{SUP,4} Y R{SUP,7} SE SELECCIONA DEL GRUPO QUE CONSTA DE UN GRUPO DE ALQUILO CICLICO, ARILO, ALQUILO C{SUB,1}C{SUB,22} SATURADO O INSATURADO (QUE PUEDE SER INTERRUMPIDO POR UN GRUPO DE ESTER, AMIDA O ETER), HIDROGENO, Y MEZCLAS DE LOS MISMOS; CADA R{SUP,5}, R{SUP,6}, R{SUP,8} Y R{SUP,9} SE SELECCIONA DEL GRUPO QUE CONSTA DE UN GRUPO DE ALQUILO CICLICO, ARILO, ALQUILO C{SUB,1}-C{SUB,22} SATURADO O INSATURADO (QUE PUEDE SER INTERRUMPIDO POR UN GRUPO DE ESTER, AMIDA O ETER), Y MEZCLAS DE LOS MISMOS; N ES DE 1 A 50; Y ES UN HIDROGENO O UN GRUPO DE METILO; Z ES UN HIDROGENO O UN GRUPO DE METILO; EN DONDE EL GRUPO AMINO DE LOS COMPUESTOS DE FORMULAS (I) A (IV) PUEDE SER PROTONADO O CUATERNIZADO CON R{SUP,10}X DONDE R{SUP,10} ES UN HIDROGENO, UN GRUPO ALQUILO C{SUB,1}-C{SUB,6}, UN GRUPO HIDROXILO ALQUILO C{SUB,1}-C{SUB,6}, UN GRUPO DE BENCILO Y MEZCLAS DE LOS MISMOS; Y X{SUP,-} ES CUALQUIER ANION COMPATIBLE.

N,n-bis(3,6-dichloro-2-methoxybenzoyloxyalkyl)aniline derivatives

PROCEDURE FOR THE PREPARATION OF BASIC ESTERS OF SUBSTITUTED HYDROXYCYCLOH hexane ANCHORIC ACYL ACIDS

N,N-bis(2-methoxy-3,6-dichlorobenzoyloxyalkyl)anilines

This invention discloses compounds of the formula WHEREIN X is alkyl; t is an integer from 0 to 3; Y is a straight or branched alkylene chain of from 2 to 3 carbon atoms. The compounds of the above description are useful as herbicides which resist leaching in the soil.

PROCESS FOR THE PREPARATION OF BASIC ESTERS OF SUBSTITUTED HYDROXYCYCLOHEXANE-CARBOXYLIC ACIDS

Procédé de préparation d'esters basiques d'acides hydroxy cyclohexane-carboxyliques substitués. On augmente fortement le rendement en composés répondant à la formule générale : Process for the preparation of basic esters of substituted hydroxy cyclohexanecarboxylic acids. The yield of compounds corresponding to the general formula is greatly increased:

PROCEDURE FOR THE PREPARATION OF 2-DIETHYLAMINE-1-METHYLETHYL CIS-1-HYDROXY- (BICYCLOHESYL) -2 CARBOXYLATE DERIVATIVES

Process for preparing quaternary ammonium carbonate esters

A process is reported for preparation of quaternary ammonium type carbonate esters which are useful as bleach precursors in detergent compositions. The process involves transesterification of low molecular weight carbonates, e.g. diphenyl carbonate, with amino functionalized alcohols, e.g. dialkylaminoalkanol. Preferably the reaction involves transesterification of diphenylcarbonate with the hydroxyl compound followed by removal of phenol. Subsequent thereto the transesterified ester is quaternized with an alkylating agent. Optionally there may be a sulfonation of phenol ester subsequent to the quaternization reaction.

Process for making solid methylglycine diacetate (mgda) alkali metal salt, and solid particles

Process for making solid methylglycine diacetate (MGDA) alkali metal salt (a), said process comprising the steps of (A) providing a 40 to 60% by weight aqueous solution of said MGDA salt having a temperature in the range of from50 to 90°C, (B) adding solid salt (a), (C) heating the resultant slurry until the salt (a) added in step (B) has dissolved at least partially, (D) allowing salt (a) to crystallize, (E) removing crystalline salt (a) from the mother liquor.

Bio-based dispersants

PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE SALTS OF 2-DIETHYLAMINO-1-METHYLETHYL-CIS-1-HYDROXY- (BICYCLOHEXYL) -2-CARBOXYLATE.

FATTY AMINOALCOOLS AND PROCESS FOR PREPARING THE SAME

La présente invention se rapporte à des composés aminoalcool et à la préparation de ceux-ci à partir d'esters gras comprenant au moins deux doubles liaisons carbone-carbone . En particulier, la présente invention concerne des composés aminoalcool gras obtenus par un procédé couplant en une seule étape une réaction d'hydroaminométhylation et une réaction d'hydrohydroxyméthylation. The present invention relates to aminoalcohol compounds and to the preparation thereof from fatty esters comprising at least two carbon-carbon double bonds. In particular, the present invention relates to fatty amino-alcohol compounds obtained by a process that couples in one step a hydroaminomethylation reaction and a hydrohydroxymethylation reaction.

Ionizable amine lipids and lipid nanoparticles

lipídios de amina ionizáveis e nanopartículas de lipídio. a divulgação fornece lipídios de amina ionizáveis e sais dos mesmos (por exemplo, sais farmaceuticamente aceitáveis dos mesmos) úteis para a entrega de agentes biologicamente ativos, por exemplo, fornecendo agentes biologicamente ativos para células para preparar células geneticamente modificadas. os lipídios de amina ionizáveis divulgados no presente documento são úteis como lipídios ionizáveis na formulação de composições à base de nanopartícula de lipídio. ionizable amine lipids and lipid nanoparticles. the disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example, providing biologically active agents to cells to prepare genetically modified cells. the ionizable amine lipids disclosed herein are useful as ionizable lipids in formulating lipid nanoparticle-based compositions.

Ionizable amine lipids and lipid nanoparticles

La descripción proporciona lípidos de amina ionizables y sales de estos (por ejemplo, sales farmacéuticamente aceptables de estos) útiles para la administración de agentes biológicamente activos, por ejemplo, la administración de agentes biológicamente activos a las células para preparar células modificadas genéticamente. Los lípidos con amina ionizables que se describen en la presente son útiles como lípidos ionizables en la formulación de composiciones con base en nanopartículas lipídicas. The disclosure provides ionizable amine lipids and salts thereof (eg, pharmaceutically acceptable salts thereof) useful for delivery of biologically active agents, eg, delivery of biologically active agents to cells to prepare genetically modified cells. The ionizable amine-containing lipids described herein are useful as ionizable lipids in the formulation of lipid nanoparticle-based compositions.

Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents

The application relates to lipids of the general Formula (A) wherein at least one of the two side chains contains a carbonate functional group (M and/or M' is -0C(=0)0-) and to empty or loaded lipid nanoparticles (LNPs) including such lipids as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

Process for the preparation of a mixture of chelating agents, mixture of chelating agents and methods of using them

The present invention relates to a process for in situ the preparation of mixtures of chelating agents by catalyzed reactions of diethanolamine derivatives with maleic acid and then with 2-halocarboxylic acid, to mixtures of chelating agents and methods using such chelating agents.

Fettamin-derivate von butyliertem hydroxytoluen für den schutz von oberflächen vor physikaler und chemischer degradierung

組成物、基板の処理方法、半導体デバイスの製造方法、化合物

本発明は、ドライエッチング残渣物の除去性に優れ、かつ、タングステンの溶解がより抑制され、さらに、被処理物に適用した後にリンス処理を行った際に残渣物が残存しにくい、半導体デバイス用の組成物を提供する。本発明の半導体デバイス用の組成物は、第１級アミノ基、第２級アミノ基、第３級アミノ基、およびこれらの塩からなる群から選択される特定基と、ヒドロキシ基とを有する繰り返し単位Ａ、および、ｐＫａが１０．０以下である官能基またはその塩を有する繰り返し単位Ｂ、を含む樹脂、ならびに、水、を含む。

Maschinengeschirrspülmittelzusammensetzungen enthaltend bleichaktivatoren, die mehrwertige percarbonsäuren bilden

阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统

本发明是关于一种阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统，涉及医药生物技术领域。解决亟需开发递送效率高、生物安全性好的阳离子脂质的问题。主要采用的技术方案为：所述阳离子脂质化合物的结构为（I）；其中，R1为包含三级胺的链状结构；R2为链状脂肪酰基；R3为具有支链的链状脂肪酰基。本发明主要开发一种递送效率高、器官靶向递送、生物安全性好的阳离子脂质化合物，以用于制备mRNA递送系统及核酸类药物。

Hochkonzentrierte wässrige lösungen von n,n- dialkyl-glyzinen und verfahren zu deren herstellung

분지형 폴리카보네이트 합성용 분지제, 그 제조방법 및 이를 이용한 분지형 폴리카보네이트

본 발명의 분지형 폴리카보네이트 합성용 분지제는 하기 화학식 1로 표시되는 것을 특징으로 한다: [화학식 1] 상기에서, R 1 및 R 2 은 각각 독립적으로 선형 또는 분지형 C 1 ∼C 30 의 알킬기, 알콕시기, C 6 ∼C 30 의 아릴기, C 1 ∼C 10 알킬치환 C 6 ∼C 30 의 아릴기이고, n은 3∼6의 정수임. 분지형 폴리카보네이트, 다관능성 분지제, 에스테르교환 반응, 말단 수산기

Procedimento per la preparazione di gamma-butirrobetaina

用于细胞内递送治疗剂的含碳酸酯的脂质化合物和组合物

本申请涉及通式(A)的脂质，其中两个侧链中的至少一个含有碳酸酯官能团(M和/或M'是‑OC(＝O)O‑)，并且涉及空的或负载的脂质纳米粒子(LNP)，其包含此类脂质以及另外的脂质，诸如磷脂、结构性脂质和PEG脂质。还包含治疗剂和/或预防剂诸如RNA的脂质纳米粒子可用于将治疗剂和/或预防剂递送至哺乳动物细胞或器官以例如调控多肽、蛋白质或基因表达。

阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统

本发明公开一种阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统；解决亟需开发递送效率高、免疫激活特性优异的阳离子脂质的问题。其中，阳离子脂质化合物的结构如式(I)所示；其中，在式(I)：X为O或N；n为2-4；m为2-4；a为0或1；R 1为包含三级胺的链状结构；R 2为直链状脂肪酰基或具有支链的链状脂肪酰基；R 3为具有支链的链状脂肪酰基。本发明主要用于开发一种阳离子脂质化合物，该阳离子脂质化合物用于制备mRNA递送系统，具有递送效率高、器官靶向递送、以及免疫激活特性优异的特点。

一种手性芳基丙酸衍生物及其药物组合物和用途

本发明公开了一种手性芳基丙酸衍生物及其药物组合物和用途，所述手性芳基丙酸衍生物如式(I)所示；所述的手性芳基丙酸衍生物具有解热镇痛抗炎作用；本发明化合物具有高活性且可局部给药，预期降低给药剂量、降低不良反应。

阳离子脂质、脂质体、脂质纳米颗粒及用途

公开了一种阳离子脂质，其具有以下通式(I)，其中A、B、C和D各自如说明书所定义。还公开了包含该阳离子脂质的脂质体和脂质纳米颗粒以及该阳离子脂质用于制备脂质体和脂质纳米颗粒的用途。

一种手性芳基丙酸衍生物及其药物组合物和用途

本发明公开了一种手性芳基丙酸衍生物及其药物组合物和用途，所述手性芳基丙酸衍生物如式(I)所示，其中各基团的定义详见说明书；所述的手性芳基丙酸衍生物具有解热镇痛抗炎作用；本发明化合物具有高活性且可局部给药，预期降低给药剂量、降低不良反应。

アミノ脂質又はその塩の製造中間体としての化合物、及びそれを用いたアミノ脂質化合物の製造方法

本発明は、炭酸エステル化反応における収率を向上させたアミノ脂質化合物の製造方法、並びに上記のアミノ脂質化合物の製造方法において使用する中間体化合物を提供することを課題とする。本発明によれば、式［１］で示される化合物又はその塩が提供される。式中、 Ｒ １ は、水素原子、又は炭素数１～１２の炭化水素基を示し、 Ｒ ２ は、炭素数２～１２の２価の炭化水素基を示し、 Ｒ ３ は、炭素数６～２２の炭化水素基を示す。

一种手性芳基丙酸衍生物及其药物组合物和用途

本发明公开了一种手性芳基丙酸衍生物及其药物组合物和用途，所述手性芳基丙酸衍生物如式(I)所示，其中各基团的定义详见说明书；所述的手性芳基丙酸衍生物具有解热镇痛抗炎作用；本发明化合物具有高活性且可局部给药，预期降低给药剂量、降低不良反应。

阳离子脂质、脂质体、脂质纳米颗粒及用途

公开了一种阳离子脂质，其具有以下通式(I)，其中A、B、C和D各自如说明书所定义。还公开了包含该阳离子脂质的脂质体和脂质纳米颗粒以及该阳离子脂质用于制备脂质体和脂质纳米颗粒的用途。

Lipid formulations for gene editing

The present disclosure relates to PEG-lipids, cationic and/or ionizable lipids and nucleic acid-lipid particle compositions comprising the same. The present disclosure also relates to methods of making, using and delivering the described lipids and lipid-containing particles.

Lipid structures and compositions comprising same

The disclosure relates to ionizable lipids and compositions comprising the ionizable lipids. Lipid-nanoparticle compositions comprised of an ionizable lipid, optionally in combination with other lipid components such as helper lipids, stabilization lipids and structural lipids, and a therapeutic agent, such as a nucleic acid, for delivery to mammalian cells or organs are described.

Compounds, compositions, and methods for reducing production of trimethylamine

Provided herein are compounds and compositions that inhibit production of trimethylamine (TMA), and methods of using the compounds, e.g., for inhibiting production of trimethylamine, and for treating disorders associated with conversion of choline to trimethylamine.